Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Growth in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 56,900 shares, a growth of 151.8% from the November 15th total of 22,600 shares. Based on an average daily volume of 36,300 shares, the short-interest ratio is currently 1.6 days. Currently, 0.5% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Akari Therapeutics in a research report on Thursday. They set a “sell” rating for the company.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX traded up $0.05 during mid-day trading on Friday, reaching $1.00. 63,952 shares of the company’s stock were exchanged, compared to its average volume of 23,546. Akari Therapeutics has a 52-week low of $0.90 and a 52-week high of $4.40. The company’s 50-day moving average is $2.01 and its 200-day moving average is $2.81.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.